BioSpace News Archive

Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.

Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.

Teaming up with a recruiter can be a smart move in a tight job market or for job seekers looking for a specialized role. To help you in your job search, we’ve outlined how to get the best out of recruiters.

Seagen’s top-selling drug hit the mark in another major indication.

Affimed will not seek accelerated approval for AFM13 as a monotherapy in advanced-stage relapsed/refractory peripheral T cell lymphoma.

Clovis Oncology officially files for Chapter 11 bankruptcy.

Tessa Therapeutics Ltd. (Tessa) today announced updated clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, were presented in a poster and oral podium presentation at the 64rd Annual Meeting of the American Society of Hematology (ASH).

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023.

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory diseases with high unmet medical needs, and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, are pleased to announce closing of their previously announced business combination.

Mirati Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for KRAZATI™, a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.